An Early Phase 1 interventional study of Behavioral Treatment in Refractory Chronic Cough, sponsored by University of Montana. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-27.
Sponsored by University of Montana · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Chronic Cough · United States.
Among the 44 studies in Chronic Cough with a site in United States, this one is the 15th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 40th registered.
142 studies on the registry are indexed under Chronic Cough; 38 are open to participants now.
Browse Chronic Cough studies →9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
University of Montana · Sites in United States
Ages 18–99
Hyfe Inc · Sites in United States
Ages 21+
Medical University of South Carolina · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 12 (40%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 50 across the 37 interventional studies, 35 across the 7 observational. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
University of Montana is the lead sponsor of 28 studies on the registry; 11 are open to participants now.
University of Montana has 5 studies filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
3 of the studies in Chronic Cough with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05110144Mayo ClinicEfficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough | 2026-12 |
| NCT05273190University of MinnesotaStimulation of the Larynx to Treat Unexplained Chronic Cough | 2027-06-01 |
| NCT06634823Medical University of South CarolinaEfficacy of Intramuscular Steroid Injection for Chronic Cough. | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Chronic Cough with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effectiveness of behavioral cough suppression therapy (BCST) in managing refractory chronic cough (RCC) within a group telehealth setting. RCC is a cough that has lasted at least 8 weeks and has not resolved with standard medical treatment. BCST is a research-based treatment provided by specialty-trained speech-language pathologists (SLPs) for patients with RCC. Although the treatment works very well for a large proportion of patients in a standard one-on-one format, there are a limited number of SLPs available to provide this treatment and patients living in rural areas do not typically have access to an SLP trained in BCST. If BCST can effectively be delivered in a group telehealth model, it would significantly improve accessibility to the treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Behavioral Treatment
Behavioral cough suppression therapy delivered in a group setting via telehealth.
Leicester Cough Questionnaire
The Leicester Cough Questionnaire is a 19-item self-report questionnaire that is valid and reliable, and repeatable every two weeks. The total possible score is 21. The higher the score the better the cough-related quality of life.
Time frame: Baseline, one-week post-treatment, and one-month post-treatment
Patient Global Impression of Severity Scale in Chronic Cough
The Patient Global Impression of Severity Scale in Chronic Cough involves the patient answering the question "how do you rate your overall current cough severity?" with options of "no problem, mild, moderate, or severe problem."
Time frame: Baseline, every treatment session (4-6 treatment sessions, one treatment session per week), and one-month post-treatment
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Jan 2025, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Montana